Sooma Oy secured U.S. FDA investigational device exemption approval to initiate a pivotal study of its transcranial direct ...

Mixed clinical results led shares of Arvinas Inc. (NASDAQ:ARVN) to close March 11 at $8.30, down $9.26, or 52%, after the company and Pfizer Inc. disclosed results from the phase III Veritac-2 study ...

Analysts were pleasantly surprised by the positive phase III data reported for Kyowa Kirin Co. Ltd./Amgen Inc.’s rocatinlimab, a T-cell rebalancing therapy, in moderate to severe atopic dermatitis.

While the U.S. has historically led the global pharmaceutical industry by pursuing both continual innovation and high quality, those strengths could become areas of weakness in times of political ...

At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full day of the conference, reports from the ...

Positive top-line data from phase II and III studies of lorundrostat for treating uncontrolled or resistant hypertension ...

Medtronic plc released positive results from a two-year trial of Evolut TAVR that demonstrated superior valve performance in patients with small aortic annuli. The SMall Annuli Randomized To Evolut or ...

For the first time, researchers have identified that inflammation – long associated with multiple sclerosis (MS) – appears to cause increased mutations that damage neurons linked to MS progression.

With millions of people suffering from chronic back pain, Discure Technologies Ltd. is hoping that its bioelectronic therapy, ...

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing Manage cookie preferences ...

A new multi-omics approach to unpicking how noncoding gene variants influence the development of common chronic diseases has ...

A slow-down in EU medical device audits due to the long-delayed transition to the EU Medical Device Regulation is leading to ...